Philippe Sauvage is recorded as CFO at Nuvation Bio Inc. (NUVB). The newest filing on record that lists Philippe Sauvage as CFO at Nuvation Bio Inc. (NUVB) is dated April 10, 2026. Nuvation Bio Inc. reported in an 8-K filed October 7, 2024 that Philippe Sauvage was appointed Chief Financial Officer and Principal Financial Officer, effective October 7, 2024. Philippe Sauvage has spoken on 6 earnings calls and 5 other investor events across 1 company, most recently for Nuvation Bio Inc. on September 9, 2026. Nuvation Bio Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nuvation Bio Inc. includes David Hung (CEO and Board Member), Moses Makunje (CFO and Chief Accounting Officer), Dr. Junyuan (Jerry) Wang (Board Member) and 7 others.
“Effective October 7, 2024 (the "Appointment Date"), the Board of Nuvation Bio Inc. (the "Company") appointed Philippe Sauvage as the Company's Chief Financial Officer and Principal Financial Officer.”
Nuvation Bio Inc. Form 8-K, filed October 7, 2024
· Read the filing
Philippe Sauvage on recent calls
“Because I think it's probably the better drug if they have low-grade or high-grade Jeff, I think what's important to keep in mind is that, of course, we are talking about several trials, but they hope, at the end, accumulate to build a whole glioma population, You have the low-grade glioma, we are doing that ex-US, in…”
“For detailed second quarter 2026 financial results, please refer to our earnings press release, which is available on our website. I will highlight a few key points from the quarter.”
“I think to your point, Leonid, to add just a little bit, what's so important to note is that, of course, we're doing our part, but we're not alone. lots of initiatives, NCCN guidelines, some state-sponsored initiatives where it becomes mandatory to test, lots of companies out there, either the testing companies or…”
“To go back to your point about short-term modeling, Robert, I think what's really important to note is that quarter-on, to David's point, we've been increasing our first-line patient number by 35%.”
“Yeah, I mean, to David's point, it was really important for us to make sure that patients could access iptrosi in the first line because there is no comparison between the experience of a patient that goes on a drug get that on iptrosi or go straight on iptrosi.”
